# Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

> **NCT00979537** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 83 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nisoldipine Extended-release Tablets, 40 mg
- **DRUG:** Sular Tablets, 40 mg

## Key facts

- **NCT ID:** NCT00979537
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2009-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979537, "Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00979537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*